Payment overview · 2025
General Payments
$841.40
41 reported records · 19 companies
Healthcare provider profile · identity verified
Paul Wayne Decker, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHENANDOAH, TX · NPI 1316033707
Verified facts
What the public records show
CMS Open Payments records show Paul Wayne Decker, MD received $841.40 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $136.91 | 16.3% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $96.05 | 11.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $85.36 | 10.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.60 | 8.8% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $66.08 | 7.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.85 | 7.6% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.46 | 5.8% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $47.49 | 5.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.87 | 4.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.22 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.41 | 2.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.04 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.75 | 2.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.35 | 2.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.35 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.75 | 2.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.66 | 2.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $16.27 | 1.9% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.93 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $841.40 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $100.77 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $96.05 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $85.36 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73.60 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $66.08 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $60.91 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.65 | 3 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 312 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 136 |
| Losartan Potassium | Losartan Potassium | 218 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 77 |
| Gabapentin | Gabapentin | 172 | 64 |
| Lisinopril | Lisinopril | 163 | 73 |
| Montelukast Sodium | Montelukast Sodium | 161 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 44 |
| Meloxicam | Meloxicam | 109 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 48 |
| Bupropion Xl | Bupropion Hcl | 102 | 46 |
| Azelastine Hcl | Azelastine Hcl | 100 | 54 |
| Metformin Hcl Er | Metformin Hcl | 98 | 46 |
| Alprazolam | Alprazolam | 97 | 28 |
| Buspirone Hcl | Buspirone Hcl | 92 | 38 |
| Trazodone Hcl | Trazodone Hcl | 89 | 39 |
| Famotidine | Famotidine | 82 | 38 |
| Metformin Hcl | Metformin Hcl | 82 | 37 |
| Simvastatin | Simvastatin | 81 | 35 |
| Omeprazole | Omeprazole | 80 | 35 |
| Tramadol Hcl | Tramadol Hcl | 71 | 26 |
| Mirtazapine | Mirtazapine | 70 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 28 |
| Methylprednisolone | Methylprednisolone | 68 | 60 |
| Furosemide | Furosemide | 67 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 24 |
| Glimepiride | Glimepiride | 65 | 29 |
| Synthroid | Levothyroxine Sodium | 65 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 36 |
| Alendronate Sodium | Alendronate Sodium | 56 | 24 |
| Cefdinir | Cefdinir | 55 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 21 |
| Azithromycin | Azithromycin | 53 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 19 |
| Ozempic | Semaglutide | 47 | 11 |
| Sertraline Hcl | Sertraline Hcl | 46 | 19 |
| Finasteride | Finasteride | 45 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 20 |
| Celecoxib | Celecoxib | 44 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 23 |
| Lorazepam | Lorazepam | 43 | 14 |
| Allopurinol | Allopurinol | 41 | 20 |
| Carvedilol | Carvedilol | 39 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 12 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Eliquis | Apixaban | 34 | 18 |
| Nifedipine Er | Nifedipine | 34 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 12 |
| Clonazepam | Clonazepam | 32 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 15 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | 11 |
| Pregabalin | Pregabalin | 31 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | 12 |
| Glipizide | Glipizide | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 23 |
| Spironolactone | Spironolactone | 24 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Valsartan | Valsartan | 22 | 12 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Prednisone | Prednisone | 17 | 17 |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $841.40 · 41 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ETERNA, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, INSPIRE, JATENZO, MOUNJARO, NEXLETOL, Ozempic, PREVNAR 20, TRELEGY ELLIPTA, TRINTELLIX, VOQUEZNA, Wegovy, XIFAXAN, XYOSTED, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error